Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine hydrochloride + povidone-iodine + triamcinolone
- Development stage
- Unknown
- Lead developer
- Sa3
- Modality
- Small Molecules
- Administration
- Topical, Parenteral
01
Overview
Bupivacaine hydrochloride + povidone-iodine + triamcinolone is a small-molecule combination kit product reportedly marketed under the name Bupivilog for local analgesia and anesthesia procedures. The combination brings together **bupivacaine hydrochloride**, an amide local anesthetic that blocks voltage-gated sodium channels to inhibit nerve impulse conduction; **povidone-iodine**, a topical antiseptic that releases free iodine and provides broad antimicrobial skin preparation; and **triamcinolone**, a synthetic corticosteroid that activates the glucocorticoid receptor to reduce local inflammation. Based on the provided context, this appears to be a procedural kit intended to support anesthesia or analgesia use, but the product is described as not having FDA-approved labeling and the specific sponsoring company could not be confirmed from the available public information.
- Brand names
- Bupivilog
- Other names
- bupivacaine hydrochloride + povidone-iodine + triamcinolone
02
Targets
NaV (Voltage-gated sodium channels)PTGER1 (Prostaglandin E Receptor 1)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on bupivacaine hydrochloride + povidone-iodine + triamcinolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine hydrochloride + povidone-iodine + triamcinolone.